Clinico-Pathological study of Paediatric Liver Tumors. by Ravindar, A
CLINICO-PATHOLOGICAL STUDY OF 
PAEDIATRIC LIVER TUMORS 
 
 
Dissertation Submitted to 
 
 
THE TAMIL NADU Dr. M.G.R. MEDICAL UNIVERSITY 
 
 
In partial fulfillment of the regulations 
for the award of the degree of 
 
 
M.Ch. BRANCH – V 
PAEDIATRIC SURGERY 
                            
                                                                                 
 
 
 
 
 
 
 
2007 – 2010 
 
 
 
INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN 
MADRAS MEDICAL COLLEGE 
THE TAMIL NADU Dr. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
AUGUST - 2010 
 CERTIFICATE 
 
This is to certify that the dissertation entitled  
“Clinico-Pathological Study of Paediatric Liver Tumors”  is a 
bonafide work done by Dr.A.Ravindar under my guidance and 
supervision during the period between 2007 – 2010 towards the partial 
fulfillment of requirement for the award of M.Ch Branch V (Paediatric 
Surgery) degree examination held in August 2010 by The Tamilnadu  
Dr. M.G.R. Medical University, Chennai.  
 
 
Prof.S.V. SENTHILNATHAN. MS., M.Ch., 
Prof. & H.O.D of Paediatric Surgery, 
Institute of Child Health & Hospital for 
Children, Egmore, 
Madras Medical College & Research Institute, 
Chennai. 
Prof. SARADHA SURESH. MD., Ph.D., 
Director & Superintendent 
Institute of Child Health & Hospital for 
Children, Egmore, 
Madras Medical College & Research 
Institute, Chennai. 
 
  
 
 
 
Dr. J. MOHANASUNDARAM.  MD., Ph D., D N B., 
Dean 
Madras Medical College & 
Government General Hospital, 
Chennai -3 
 
DECLARATION 
 
I solemnly declare that the dissertation entitled  
“Clinico-Pathological Study of Paediatric liver tumors” is the original 
work done by me at The Institute of Child Health & Hospital for 
Children, Egmore, during the M.Ch. course (2007 to 2010), under the 
guidance and supervision of Prof. S.V. Senthilnathan MS., M.Ch., 
Professor and H.O.D. of Paediatric Surgery. The dissertation is submitted 
to THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY towards 
the partial fulfillment of requirement for the award of M.Ch.  
(BRANCH – V ) IN  PAEDIATRIC SURGERY.  
 
 
   
Place : Chennai                                      Dr. A.RAVINDAR  
Date   : 26th  May, 2010 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
It gives me immense pleasure to express my deep sense of 
gratitude to Prof. S.V. Senthilnathan. MS., M.Ch., Prof. and H.O.D. of 
Paediatric Surgery, for his able guidance during the course of  study and 
in preparation of this dissertation.  
I sincerely thank Prof. P. Mohan MS., M.Ch., and  
Prof.K.Saravanabavan, MS., M.Ch., for helping me to complete this 
dissertation.  
I sincerely thank my former H.O.D. Prof.P.Jayakumar, and 
Prof.S.Philip Chandran  for their constant encouragement and support 
in completing the study. 
I express my thanks to Assistant Professors Dr.R.Senthilnathan, 
Dr.S.R.Reghunandan, Dr.J.Krishnamohan, Dr.V.Giridharan, 
Dr.D.Vembar, Dr.R.Velmurugan, Dr.C.Sankkarabarathi,  
Dr. S. Kasi, Dr. G. Hariharan, Dr.J.Muthukumar, Dr.Mohankumar, 
and Dr.C.Saravanan for their encouragement during the course of study. 
I sincerely thank Dr. C. Natarajan Department of Radiology,   
Prof. T.B. Uma Devi, Dr.Selvambigai and Dr.Jaiganesh Department of 
Pathology,  Prof. Kalaiselvi and Dr. Rajasekar Department of Medical 
Oncology and Dr. R. Vijayalakshmi, Department of Radio Therapy, 
Institute of Child Health,  Chennai for helping me to complete this study.  
I thank Prof. Saradha Suresh M.D., Ph.D,  Director and 
Superintendent, Institute of Child Health & Hospital for Children, 
Egmore, for permitting me to use all resources for my dissertation work.  
I thank my family members for their support towards completing my 
study successfully. Last but not the least, I heartily thank the patients and 
their parents for their kind support and cooperation for successful 
completion of this study. 
 CONTENTS 
 
 
S.NO TOPICS PAGE NO 
1 INTRODUCTION       1 
2 AIM OF THE STUDY 2 
3 REVIEW OF LITERATURE 3 
4 MATERIALS AND METHODS  31 
5 OBSERVATIONS 38 
6 DISCUSSION 47 
7 CONCLUSION 58 
8 ANNEXURES   
 BIBLIOGRAPHY  
 PROFORMA   
 MASTER CHART   
 
 1
INTRODUCTION 
Primary neoplasms of the liver occur rarely during childhood and 
constitute only 0.3-2% of all pediatric tumors [1]. However, they 
comprise a variety of entities including benign and malignant epithelial, 
as well as mesenchymal tumors, the most common of these being 
hepatoblastoma. Other malignant liver tumors are quite rare and include 
biliary rhabdomyosarcoma, angiosarcoma, rhabdoid tumor, and 
undifferentiated sarcoma [2]. The commonly seen benign liver tumors in 
children are infantile hemangioma, mesenchymal hamartoma, and focal 
nodular hyperplasia. Rare benign tumors are hepatic adenoma and 
teratoma [2].  Clinical presentation, especially in young children is 
relatively uniform with abdominal enlargement and a painless tumor, and 
often specific symptoms develop late. Prerequisites for clinical diagnosis 
are a comprehensive laboratory workup and good quality imaging mainly 
with ultrasound, as well as CT and/or MRI scans. Histological diagnosis 
is essential for differential diagnosis. Major progress has been achieved 
during the last decades in the treatment of malignant liver tumors in 
children, both in chemotherapy and in surgical management [3]. Surgery 
is the mainstay of treatment for all benign and malignant liver tumors [1]. 
Prognosis nowadays usually is good in all benign tumors and 
hepatoblastoma, as well as in some other rare malignancies, but dismal in 
hepatocellular carcinoma and other chemotherapy non sensitive 
malignant tumors. The future in the treatment of children with advanced 
malignant liver tumors lies in primary liver transplantation.   
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AIM OF THE STUDY 
1. To study the incidence and age distribution of various liver tumors 
in children. 
2. To study the mode of presentation and clinical profile of both 
benign and malignant liver tumors. 
3. To study the role of tumor markers and imaging techniques in the 
preoperative workup of these tumors. 
4. To study the role of primary liver resections in achieving disease 
free survival. 
5. To assess the effectiveness of adjuvant and neoadjuvant 
chemotherapy in downstaging the disease.  
6. To study the outcome based on morbidity and mortality profile of 
the children treated within the period of study. 
7. To identify pitfalls (if any) in the management protocol to improve 
the long term survival. 
8. To suggest guidelines for future management. 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY 
The liver is the third most common site for intra-abdominal 
malignancy in children, following adrenal neuroblastoma and Wilms 
tumor [4]. Two thirds of liver tumors in children are malignant [1]. 
Unlike liver tumors in adults, where the predominant histology is 
hepatocellular carcinoma, hepatoblastoma accounts for two thirds of liver 
tumors in children.  
Hepatoblastoma is associated with Beckwith-Wiedemann 
syndrome, familial adenomatous polyposis, hemihypertrophy and low 
birth weight [5][6][7][8][9]. The most common genetic aberrations 
involve chromosomes 1p, lq, 2q, 4q, 7q, 8q, 12p, 17q, 20, 22q, Xp, and 
Xq [10][11][12]. Hepatoblastoma has been associated with stabilizing 
mutations of beta-catenin and activation of Wnt/beta-catenin signaling 
[13]. Up-regulation of insulin-like growth factor 2 has also been observed 
in hepatoblastoma [14]. VLBW infants are also at a higher risk of 
developing advanced hepatoblastoma [15]. The cause of hepatoblastoma 
remains unclear, but recent theories suggest that hepatoblastoma is 
derived from a pluripotent hepatic stem cell or oval stem cell that can 
differentiate into both hepatocytes and biliary epithelial cells.  
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Hepatocellular carcinoma occurs predominantly in the setting of 
underlying liver disease due to hepatitis B virus and cirrhosis. In young 
children, hepatocellular carcinoma has been associated with tyrosinemia 
and other inherited metabolic disorders [16].  
One third of liver tumors are benign. Benign tumors of the liver in 
children include vascular tumors, hamartomas, adenomas, and focal 
nodular hyperplasia. Benign liver tumors interestingly tend to occur in 
patients with other conditions. Hepatic adenomas have long been 
associated with the use of oral contraceptive pills in adults [17]. Children 
are at risk for hepatic adenomas when they have received androgen 
therapy for aplastic anaemia, have chronic iron overload from transfusion 
in beta-thalassemia, or have received corticosteroids after renal 
transplantation [18]. Patients with type 1 glycogen storage disease are at 
increased risk for hepatic adenoma [19] and focal nodular hyperplasia 
[20].  Liver hamartomas may occur in children with tuberous sclerosis 
[21].  
Other liver malignancies in children include sarcomas, germ cell 
tumors and rhabdoid tumors. The histology and anatomy of a pediatric 
liver tumor guides the treatment and prognosis. 
CLINICAL PRESENTATION 
There exists a relatively typical distribution of liver tumors in 
different age groups, which are however, not totally exclusive, since 
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rarely typical tumors of infancy have been observed in adults and vice 
versa. The age distribution and relative frequency are shown below in 
table1 [1]: 
 
Most children with a primary liver tumor present with abdominal 
distention and a palpable mass often without other signs of severe disease 
[22][23]. Anemia is often present. Only in advanced stage of the disease, 
the overall status deteriorates and the children develop abdominal pain, 
weight loss, nausea, vomiting, ascites, and in case of pulmonary 
metastases progressive respiratory problems. Jaundice, signs of hepatic 
insufficiency or an incidental rupture of the tumor with intraabdominal 
bleeding are very rare. Thus, many tumors reach a considerable size 
before treatment can be initiated. However, some specific symptoms are 
associated with the different tumors, such as fever and thrombocytosis 
with hepatoblastoma and precocious puberty secondary to human 
chorionic gonadotropin (HCG) or rarely testosterone production in 
hepatoblastoma or germ cell tumors. High output cardiac insufficiency 
due to arterio-venous shunting in the tumor and platelet sequestration and 
consumptive coagulopathy (Kasabach-Merritt syndrome) can be 
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encountered in young infants with a hemangioma or 
hemangioendothelioma of the liver, who often also show hemangiomas of 
the skin and other organs. 
LABORATORY INVESTIGATIONS 
ROUTINE BLOOD INVESTIGATIONS 
Routine laboratory tests should include Complete blood counts, C-
reactive protein, transaminases, glutamyl transferase, alkaline 
phosphatase, and bilirubin in all patients. Virological titers for hepatitis 
A, B, and C, HIV-1and EBV should be done in suspected cases of 
hepatocellular carcinoma. Thrombocytosis is present in 60% of cases 
[24]. 
TUMOR MARKERS 
The most important and sensitive laboratory test for 
hepatoblastoma and hepatocellular carcinoma is serum AFP level, 
because it is highly elevated in over 90% of all hepatoblastoma and 
moderately elevated in 70% of Hepatocellular Carcinoma patients 
[25][26]. It can also be highly elevated in malignant teratoma and yolk 
sac tumors of the liver. Slightly elevated levels may also be found in 
other tumors, as well as after damage or during regeneration of liver 
parenchyma. Falsely elevated serum AFP levels can be noted in hepatitis, 
cirrhosis, hemangioendothelioma, germ cell tumor, testicular tumor and 
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gallbladder carcinoma. Normal AFP levels have been observed with both 
well-differentiated and immature hepatoblastomas and frequently occur 
with the fibrolamellar variants of hepatocellular carcinoma [25][27][28]. 
Normal AFP level in hepatoblastoma indicates that these tumors are 
biologically more aggressive [29][30]. Serum AFP levels can be used to 
monitor chemotherapeutic efficacy and to detect disease recurrence. AFP 
levels must be interpreted with caution in children as there is a wide 
range of AFP in the first years of life, with normal levels exceeding 
500,000ng/ml in neonates and 300 ng/ml in 3 year old children. 
The other tumor markers of liver include: 
HCG hepatoblastoma, malignant germ cell 
tumors. 
Testosterone hepatoblastoma. 
Ferritin Hepatocellular carcinoma. 
CEA Hepatocellular carcinoma. 
LDH many malignant tumors. 
NSE, catecholamines   liver infiltration by neuroblastoma. 
 
Rarely, a Hepatoblastoma secreting Beta-HCG is associated with 
sexual precocity. 
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IMAGING 
Imaging is helpful both for diagnostic purposes and to assess tumor 
resectability. Ultimately, imaging should delineate the size and location 
of tumors, evaluate for metastastic disease, and determine whether 
vascular invasion of the portal vein, hepatic veins, or inferior vena cava is 
present. Although advances in imaging have improved the ability to 
predict resectability, the ultimate assessment is made in the operating 
room by the surgeon. 
ULTRASOUND 
The best and easiest technique for imaging of suspected tumor in 
the liver is ultrasound, which can be used repeatedly without anesthesia 
even in young children. With this technique, a tumor can be clearly 
localized to the liver and its internal structure can be detected [1]. 
Ultrasonography is helpful for the initial evaluation to assess vascular 
involvement. Doppler ultrasonography is helpful in identifying the 
tumor’s relationship to neighboring vessels and in diagnosing venous 
thrombosis and vascular shunts within the tumor [31].  Malignant liver 
neoplasms are usually well-defined hyperechoic (solid) lesions on 
ultrasonography [15]. It has also been used intraoperatively to aid in 
determining vascular involvement and tumor resectability. 
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CT AND MRI SCAN 
The tumor type, size, location and borders of a liver tumor and its 
resectability can be better determined by CT or MRI scan, the latter 
giving better contrast between normal liver and neoplastic tissue [33]. 
With a combination of these techniques, the individual lesion can be 
identified as, either, solitary or multifocal, solid or cystic, with 
homogeneous or inhomogeneous internal structure. CT and MRI scans 
can also demonstrate invasion into vessels or extrahepatic structures and 
enlargement of lymph nodes. Liver tumors have homogeneous 
hypointensity on Tl-weighted images and hyperintensity on T2-weighted 
images [34]. Three-dimensional reconstruction can significantly enhance 
the surgeon's ability to predict resectability. 
CONVENTIONAL ANGIOGRAPHY & MR ANGIOGRAPHY 
Conventional angiography was used in the past to delineate the 
anatomy of the hepatic vasculature, but with the availability of MR 
Angiography planning of resection of tumors especially those with 
noncharacteristic features in imaging, such as malignant tumors with a 
completely homogeneous internal structure or hepatoblastoma presenting 
as a solitary cyst can be now done with ease. MR Angiography has made 
conventional angiography superfluous [35]. Angiography can still be 
used in some cases to perform selective chemoembolisation as a 
therapeutic intervention. 
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HEPATIC SCINTIGRAPHY 
This helps in the identification of focal nodular hyperplasia with an 
increased 99m-Technetium-sulfur uptake in contrast to hepatic adenoma. 
CT CHEST / CEREBRAL MRI / BONE SCAN 
Aside from a conventional thoracic radiograph, a CT scan of the 
chest is essential to find or rule out pulmonary metastasis. In HCC it is 
necessary to expand imaging in search for metastases applying cerebral 
MRI as well as bone scan. 
FDG PET SCAN 
There has been very little experience with positron emission 
tomography in pediatric liver tumors. In combination with an MRI scan, 
PET scan is capable of localizing recurrent hepatoblastoma and HCC 
somewhat more precisely than MRI alone. 
DIFFERENTIAL DIAGNOSIS AND HISTOLOGY 
The ultimate diagnosis of the type of liver tumor is made with a 
biopsy and a histological examination is mandatory for all primary 
pediatric liver tumors either after an initial resection or before initiation 
of chemotherapy in unresectable cases. This can be done percutaneously, 
laparoscopically, or through the open approach. Fine needle aspiration 
can be sufficient for diagnosis and some even suggest that neoadjuvant 
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chemotherapy can be started on the basis of clinical features only [25].  
Owing to the significant error rate in clinical diagnosis, a biopsy in all 
cases is strongly advocated by many [36]. 
NEEDLE BIOPSY 
It is still a controversy, whether a needle biopsy is sufficient for a 
histological diagnosis. Some advocate that a cytological examination of 
needle aspiration can differentiate hepatoblastoma, hepatocellular 
carcinoma and benign lesions [37][38] but it is generally felt that needle 
biopsies are insufficient. Some consider that a Tru-cut needle biopsy 
permits sufficient histological workup, is simple with a low rate of 
complications and ideal for children with an unresectable tumor [39]. 
LAPAROSCOPY OR LAPAROTOMY AND BIOPSY 
This is considered to be the most ideal as it offers the advantage of 
direct visualization of the liver tumor and therefore helps in taking a more 
representative sample from the lesion and at the same time it is possible 
for surgical assessment of resectability and also sample enlarged lymph 
nodes for accurate staging. 
The distribution of the various malignant and benign primary 
hepatic tumors is shown in table 2: 
 12
Table 2 
Incidence of Primary Hepatic Tumors in Childhood 
Tumor % of Patients 
Malignant 
 Hepatoblastoma 
 Hepatocelluar Carcinoma 
 Sarcoma 
 
43 
23 
6 
Benign 
 Benign Vascular tumor 
 Mesenchymal Hamartoma 
 Adenoma 
 Focal nodular hyperplasia 
Other 
 
13 
6 
2 
2 
5 
 
Hepatoblastoma and hepatocellular carcinoma are of epithelial 
origin and account for more than 90% of malignant liver neoplasms [40]. 
Primary liver neoplasms can also be of mesenchymal origin, of these, 
sarcomas are the most common (Undifferentiated embryonal sarcomas 
and Rhabdomyosarcoma).  Other reported malignancies include the 
malignant transformation of mesenchymal hamartoma, angiosarcoma, 
cholangiocarcinoma, rhabdoid tumor, immature teratoma, and 
choriocarcinoma. Metastatic disease to the liver is relatively uncommon 
in children. 
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BENIGN TUMORS OF THE LIVER 
Benign tumors may be epithelial (focal nodular hyperplasia, 
hepatocellular adenoma), mesenchymal (mesenchymal hamartoma), 
vascular (infantile hemangioendothelioma, cavernous hemangioma), or 
others (teratoma, inflammatory pseudotumor). The most common benign 
liver tumor in infants is hemangioma. Commonly seen benign tumors in 
toddlers are mesenchymal hamartoma and focal nodular hyperplasia. 
Hepatic adenoma is almost exclusively a disease of older children.  
INFANTILE HEPATIC HEMANGIOENDOTHELIOMA  
Infantile Hepatic Hemangioendothelioma (IHH) is the most 
common benign liver tumor in children. IHH is now being diagnosed 
prenatally, and similar to affected neonates, the fetus may be 
asymptomatic or profoundly ill [41][42]. Children with symptoms present 
before 6 months of age 80% of the time, with many presenting in the 
newborn period [42][43][44]. The most common finding on examination 
is hepatomegaly. The severity of the disease may vary from 
asymptomatic children to those with life threatening CHF, abdominal 
compartment syndrome, and severe thrombocytopenia. 50% of children 
have a cutaneous hemangioma also [44]. On ultrasonography, lesions 
appear as multifocal, echolucent nodules with high flow vessels or as 
solitary heterogenous echogenic lesions [45]. On a plain CT scan the 
lesions have a low attenuation and on contrast administration they 
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enhance diffusely or centripetally [45]. MRI reveals the extent of the 
disease, the flow characteristics, and the flow structure [45]. AFP and 
catecholamine levels should be obtained to rule out a hepatoblastoma or a 
stage 4S neuroblastoma [46]. 
Dehner and Ishak identified two types of IHH are Type 1, which is 
more common and is characterized by an orderly arrangement of dilated 
and compressed endothelium lined vascular spaces supported by reticulin 
fibres with benign cytologic features. Type 2 lesions have a more 
aggressive appearance with more complex and irregular branching 
structures within the vascular lumens. 
The treatment depends upon the severity and the location of the 
lesion. If the child is asymptomatic with little hepatomegaly, observation 
is the appropriate therapy. Percutaneous or open biopsy is discouraged 
because of the risk of significant hemorrhage. In a symptomatic child 
pharmacological control with corticosteroids [42][43][44], 
interferon(IFN) [47][48], vincristine [49], or cyclophosphamide [50] 
should be tried. Embolisation is most effective in children with disease 
restricted to only a few segments. Although hepatic artery ligation was 
recommended in the past, it prevents effective embolisation and thus 
should be avoided. Hepatic resection or liver transplantation may be 
needed if disease progression occurs despite medical management [51]. 
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HEMANGIOMA 
Hemangioma  is the most common benign liver tumor in adults; in 
children, however hemangiomas are usually incidental findings in 
asymptomatic patients [52]. Hemangiomas have widely dilated, 
nonanastamotic vascular spaces lined by flat endothelial cells and 
supported by fibrous tissue [52]. The natural history for hemangiomas is 
spontaneous regression in the first 2 years of life. Medical management 
consists of high-dose steroids (3-5 mg/kg/d) for 3-5 weeks. However, the 
response time is slow, and lesions can rebound once the drug is stopped. 
Focal lesions can be treated with complete surgical excision or with 
selective hepatic artery embolization. The overall prognosis for these 
benign hepatic tumors in children is good.  
MESENCHYMAL HAMARTOMA 
Mesenchymal hamartomas are the second most common benign 
liver tumor, comprising 5% of liver tumors in children [40].  They are 
known by various names including pseudocystic mesenchymal tumor, 
giant cell lymphangioma, cystic hamartoma, bile cell fibroadenoma and 
cavernous lymphangiomatoid tumor. The term mesenchymal hamartoma 
was coined by Edmondson in 1956 [53]. They are typically diagnosed 
when the patient is younger than 2 years. They can sometimes be seen on 
a prenatal ultrasound, but usually presents as an asymptomatic abdominal 
mass or after a period of rapid growth with compression of adjacent 
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tissues leading to vena caval compression, feeding difficulties, and 
respiratory distress secondary to upward pressure on the diaphragms. The 
right lobe is more commonly involved and on ultrasound or CT scan they 
have a pathognomonic appearance of a single large fluid filled mass with 
fine internal septations and no calcifications [54].  The AFP levels are 
usually normal but may be mildly elevated. Mesenchymal hamartoma 
usually follows a benign course [53] although there are reports of 
sarcoma arising from these lesions. The treatment of choice is complete 
surgical resection as lesions may recur with incomplete removal of the 
tumor. 
FOCAL NODULAR HYPERPLASIA AND HEPATIC ADENOMA 
Focal nodular hyperplasia (FNH) and hepatic adenomas are rarely 
seen in childhood. Both of these benign lesions have an association with a 
high estrogen environment and frequently occur in adolescent girls. 
Hepatic adenomas are associated with oral contraceptive use, type 1 
glycogen storage disease [55].  
A characteristic central scar on CT scan is pathognomonic for 
FNH. Unenhanced CT scans show a hypodense well-defined lesion. A 3-
phase CT scan is the optimal study to make the diagnosis of FNH, 
including an arterial phase, portal venous phase, and delayed images. 
During the arterial phase, an FNH appears as an early contrast-enhanced 
homogenous lesion that becomes isodense with the normal liver 
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parenchyma on delayed images. Differentiating FNH from adenomas 
may require technetium sulphur colloid scan, which shows uniform 
uptake by FNH lesions. Open biopsy may be required for definitive 
diagnosis in rare circumstances. 
FNH lesions have no malignant potential and are often 
asymptomatic. Elective resection may be done to prevent spontaneous 
rupture and hemorrhage or they can be followed up with serial US 
monitoring. If the lesions are symptomatic or rapidly enlarging, complete 
surgical resection, embolization, or hepatic artery ligation may be used 
for treatment.  
Hepatic adenomas are treated with complete surgical excision 
because these lesions have a small risk for rupture, hemorrhage, or 
malignant transformation to hepatocellular carcinoma.  
TERATOMA 
Hepatic teratoma in children is very rare. These children are 
younger than 1 year, and calcification is usually present within the lesion.  
Serum AFP levels may only be mildly elevated in comparison to 
hepatoblastoma. Resection is the treatment of choice owing to risk of 
malignancy from any immature elements of the tumor. 
 18
INFLAMMATORY PSEUDOTUMOR 
Inflammatory pseudotumor of the liver is rare. It is seen in children 
older than 3 years. Because it is predominantly solid, it is difficult to 
differentiate it from other benign or malignant tumors by imaging studies. 
Fever, leukocytosis, and high C-reactive protein level in a child with a 
solid liver mass and normal AFP level are suggestive of an inflammatory 
pseudo tumor. Because it is difficult to diagnose this lesion without a 
large biopsy or resection of the lesion, most children undergo resection, 
which is curative. 
MALIGNANT TUMORS OF THE LIVER 
HEPATOBLASTOMA  
Hepatoblastoma (HB) is the most common primary hepatic 
malignancy in childhood, accounting for 43% of all pediatric liver tumors 
[1].  Hepatoblastomas are composed of cells resembling the developing 
fetal and embryonic liver, hence the classification as an embryonal tumor. 
Most commonly, these tumors present in the right lobe of the liver. 
Histologically, these tumors can be divided into epithelial or mixed 
epithelial/mesenchymal tissue. The epithelial type is subdivided into fetal, 
embryonal, macrotrabecular, and small cell undifferentiated types. The 
fetal histology carries the most favorable prognosis [56] and the Small 
cell undifferentiated the worst prognosis [29].  
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The typical presentation is a child younger than 3 years with an 
abdominal mass, anemia, failure to thrive, and vomiting. An increased 
risk of hepatoblastoma exists in association with hemihypertrophy, 
Beckwith-Wiedemann syndrome and familial adenomatous polyposis.  
Associated laboratory abnormalities include an elevated AFP and 
thrombocytosis. More that 90% of patients with hepatoblastoma have 
elevated AFP levels and tumors that do not express AFP at diagnosis are 
felt to be biologically more aggressive [29][30]. Ultrasound identifies the 
liver as the organ of origin and the extent of tumor within the liver. 
Doppler evaluation can be used to evaluate the patency of the inferior 
vena cava, the hepatic veins, and the portal vein. CT scans of the 
abdomen and chest are used to assess resectability and evaluate for the 
presence of pulmonary metastasis. Hepatic angiography or MRI 
angiography is frequently helpful preoperatively to determine 
resectability because it delineates the vascular anatomy more precisely.  
Cure from hepatoblastoma mandates a complete gross resection of 
the primary tumor at some point during the treatment regimen. Even 
though about half of the tumors can be resected by primary operation, 
preoperative chemotherapy should precede the operation in case of large 
tumors even when there is possibility of resection [58]. This strategy 
helps to preserve more mass of healthy hepatic tissue and decrease 
intraoperative and postoperative complications. If the tumor is 
unresectable at presentation (50% of tumors), then neo-adjuvant 
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chemotherapy is started before definitive resection. Even if unresectable 
at diagnosis, most hepatoblastomas are chemosensitive, especially to 
“platinum” containing chemotherapeutic agents and cisplatin remains the 
backbone of any chemotherapy regimen. Unresectability is largely due to 
the size of the tumor with attendant invasion of hepatic vessels and the 
inferior vena cava (IVC) [57]. Adequate response to chemotherapy is 
observed in 70% of patients who then go on to complete resection 
followed by additional postoperative chemotherapy. Orthotopic liver 
transplantation is an option in children with unresectable primary tumors 
and without demonstrable metastatic disease after neoadjuvant 
chemotherapy and pulmonary metastasectomy. AFP is considered an 
early marker for recurrence, and elevated levels should prompt thorough 
investigation.  
HEPATOCELLULAR CARCINOMA  
Hepatocellular carcinoma is the second most common malignancy 
of the liver in children. Hepatocellular carcinoma (HCC) accounts for 
23% [1] of pediatric hepatic malignancies and occurs in older children 
than hepatoblastoma. Predisposing conditions include hepatic fibrosis and 
cirrhosis secondary to metabolic liver disease, tyrosinemia, alpha 1 
antitrypsin deficiency, type 1 glycogen storage disease, viral hepatitis 
(hepatitis B & C), primary sclerosing cholangitis,. Less commonly, HCC 
occurs in children without preexisting liver disease.  
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Patients with HCC typically present with abdominal pain caused by 
the large size of the lesion. Associated weight loss, anemia, and fever 
may also be present. Liver function tests are routinely elevated; the AFP 
is elevated in half of the cases. The fibrolamellar variant is rarely 
associated with cirrhosis and rarely produces AFP. Metastases usually 
occur in the lung and lymph nodes. More than 70% of these tumors are 
considered unresectable at the time of presentation and are relatively 
chemoresistant. Complete surgical resection or transplantation of 
localized disease is often the only hope. Multifocal tumors carry a very 
high relapse rate. New treatment modalities include metronomic 
chemotherapy and adjuvant anti-angiogenic therapy and  are the target of 
investigation [59][60][61]. 
SARCOMA OF THE LIVER 
Primary sarcoma of the liver is a rare entity. Undifferentiated 
(embryonal) sarcoma is an aggressive tumor with an unfavourable 
prognosis. Recent multimodal approaches has led to a reported survival 
of up to 70% of children [62][63].  Angiosarcoma of the liver is an 
aggressive malignant subtype with a poor prognosis. Sporadic case 
reports of malignant transformation of infantile hemangioma to 
angiosarcoma have been reported [64][65].  Embryonal or botryoid 
rhabdomyosarcomas arising from biliary ducts typically present with 
jaundice secondary to biliary obstruction and are known to have a 
favorable prognosis as they are chemo and radio sensitive. Rhabdoid 
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tumor of liver is an aggressive tumor seen in toddlers and school children 
and is chemoresistant and fatal. 
HEPATIC METASTASES  
Hepatic metastases in the pediatric population arise from a variety 
of primary malignancies, including neuroblastoma, Wilms tumor, 
rhabdomyosarcoma, rhabdoid tumor, non-Hodgkin lymphoma, adrenal 
cortical carcinoma, and osteogenic sarcoma. Current criteria for resection 
of these hepatic metastases include control of the primary tumor, a 
solitary or limited number of metastases, and a reasonable expectation of 
prolonged survival. 
STAGING 
Multiple staging systems have been proposed to classify both 
hepatoblastoma and hepatocellular carcinoma. 
Pediatric Oncology Group (POG) staging system 
The Pediatric Oncology Group (POG) in the United States uses a 
staging system based on the postoperative extent of disease. Although the 
POG staging system is useful in determining the postoperative prognosis, 
it does not provide information on the preoperative extent of disease. The 
staging is shown in table 3. 
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Table 3 
Staging for Hepatoblastoma and Hepatocellular Carcinoma 
Stage Description 
I Complete resection 
II Microscopic residual tumor 
III Macroscopic residual tumor 
IV Distant Metastasis 
 
PRETEXT (PRE Treatment EXTent of disease) 
To describe the extent of the primary tumor, before and during 
therapy [66], the International Society of Pediatric Oncology (SlOP) 
developed the PRETEXT (pretreatment extent of disease) staging system. 
It also helps to assess tumor response and resectability before and after 
neoadjuvant chemotherapy, The PRETEXT system is based on radiologic 
findings and describes both the number and the location of involved liver 
sectors and takes into account invasion of the hepatic and portal veins as 
well as extrahepatic and metastatic disease. Imaging includes a spiral CT 
followed by contrast administration and/or MRI with gadolinium. This 
system has the advantage of being independent of therapeutic strategies 
and the individual surgeon’s judgment and therefore has very good 
reproducibility and an excellent predictive value as regards the prognosis 
[67][68]. 
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TREATMENT 
SURGERY 
The primary goal of surgery is complete anatomic resection of the 
tumor, both macro and microscopically which is of paramount 
importance in cure of liver cancers in children. Liver is one of the most 
difficult organs a surgeon can repair because of its friable tissue with an 
intricate network of ducts, veins and arteries. Major vascular structures, 
particularly the hepatic veins and inferior vena cava are prone to bleeding 
during resection. On the other hand, liver’s regenerative capability and 
large functional reserve allow major resections of up to 80% of its tissue 
[69][70]. Successful hepatic resection requires careful planning and 
supportive care.  
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A sound knowledge of the three-dimensional segmental anatomy 
of the liver as described by Couinaud [71] as shown in figure, vascular 
occlusion techniques and expertise in performing different types of liver 
resections is essential for a successful outcome. Intraoperative ultrasound 
is useful in confirming the location of major vessels and other structures. 
Complete tumor resection can be easily achieved with a partial 
hepatectomy when the intrahepatic extent is limited to one or two 
sections (PRETEXT 1 & 2). When the tumor involves three sections 
(PRETEXT 3), preoperative neoadjuvant chemotherapy makes lesions 
considered “unresectable’ become resectable with a trisegmentectomy 
[1]. In centrally located lesions, resection of segments 4,5 & 8 (central 
hepatectomy) can be performed.  
In general, nonanatomic, atypical liver resections should be 
avoided because of a higher rate of incomplete tumor resection, local 
relapse and postoperative complications [72].  
Standard anatomic resections can lead to the loss of a significant 
percentage of liver parenchyma but most children with otherwise normal 
liver parenchyma can easily adapt to major resections with compensatory 
hyperplasia of the remaining liver within 3 months. The terminology used 
to define the anatomical limits of resection was given by Goldsmith and 
Woodburne and is shown in the table below along with the equivalent 
nomenclature in the Couinaud classification [86][87]:  
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Terminology of Goldsmith and 
Woodburne 
Terminology of Couinaud 
Right Hepatic Lobectomy Right hepatectomy, segments V, 
VI, VII, VIII 
Left Hepatic Lobectomy Left hepatectomy, segments II, III, 
IV 
Extended Right Hepatic Lobectomy Extended right hepatectomy, 
segments IV,V, VI, VII, VIII, 
sometimes I 
Extended Left Hepatic Lobectomy Extended left hepatectomy, 
segments II, III, IV, V, VIII, 
sometimes I 
Left Lateral Segmentectomy Left lobectomy,, segments II, III 
Central Hepatic Resection 
(Mesohepatectomy) 
Segments IV, V, and VIII 
 
Several instruments have been developed to help the surgeon 
minimize blood loss during dissection. These devices are welcome 
adjuncts to the basic techniques of finger fracture and electrocautery.  
The Cavitron Ultrasonic Surgical Aspirator (CUSA®) is an 
innovative tool for resecting hepatic parenchyma, as it reduces 
intraoperative blood loss and perioperative morbidity and has become a 
standard surgical tool for liver resection. First introduced by Hodgson for 
liver surgery in 1984, it is a hand held instrument consisting of an 
acoustic vibrator, perfused with saline, which disrupts the liver 
parenchyma by producing a cavitational effect. CUSA®, combined with 
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bipolar cautery and a saline irrigation system, allows hepatic parenchyma 
resection in a bloodless manner. As the safety of liver resection depends 
mainly on the control of bleeding during parenchymal resection, the use 
of this technique has decreased morbidity in children undergoing major 
hepatic resections and specially those who have a smaller hepatic 
functional reserve.  
The other adjuncts used to facilitate a bloodless parenchymal 
dissection include water jet dissection, argon plasma spray coagulation, 
Nd:YAG lasers, linear cutting staplers, LigaSure and Floating Ball 
apparatus by TissueLink. 
ADJUVANT THERAPY 
CHEMOTHERAPY 
Although cure ultimately requires complete resection, cisplatin 
containing chemotherapy remains the mainstay of adjuvant therapy for 
hepatoblastoma and hepatocellular carcinoma. Neoadjuvant 
chemotherapy has been advocated by the SIOPEL group for childhood 
hepatoblastoma [66] for the purpose of downstaging the disease, 
improving the likelihood of complete resection, and ultimately improving 
long-term survival. Up to 50% to 70% of stage III hepatoblastomas can 
be rendered resectable after neoadjuvant chemotherapy [73]. The 
disadvantage of neoadjuvant therapy is that nonresponders can experience 
disease progression, and ultimately the tumor can be upstaged or become 
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unresectable. Prolonging chemotherapy beyond the total number of 6-8 
courses, administered every 3 weeks, is unlikely to result in an 
unresectable tumor becoming resectable and Orthotopic Liver 
Transplantation (OLT) should be considered early. The commonly used 
drugs include cisplatin, vincristine, 5-fluorouracil and doxorubicin. 
RADIOTHERAPY 
Radiation therapy has a limited role in the management of 
hepatoblastoma and hepatocellular carcinoma. Current cooperative trials 
provide for permissive use of radiation therapy in children with residual 
disease. However, the ultimate goal remains complete surgical resection 
as the only effective means of cure. 
ABLATIVE THERAPIES 
Patients with lesions that cannot be anatomically resected and those 
who are not candidates for transplantation can be considered for local 
ablative therapies. These include chemoembolization, radiofrequency 
ablation, percutaneous injection of ethanol, and cryoablation. Ablative 
therapies offer palliation and may prolong survival but rarely achieve a 
cure. Alternatively, ablative therapies can act as a bridge to 
transplantation until a suitable donor becomes available. 
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NOVEL THERAPIES - SUICIDE GENE THERAPY [74]. 
This strategy was developed in the hope of avoiding the systemic 
side effects of standard adjuvant therapies. It involves the expression of a 
gene that converts a membrane permeable nontoxic prodrug into a toxic 
agent (suicide drug) in the tumor cells only and therefore causing 
destruction of the tumor cells only. 
LIVER TRANSPLANTATION 
Ultimately, up to 6% of patients with hepatoblastoma will require 
orthotopic liver transplantation [6][75]. The SIOPEL guidelines [76] for 
early referral for liver transplantation include: 
i. Multifocal PRETEXT 4 hepatoblastoma. 
ii. Large, solitary PRETEXT 4 hepatoblastoma, involving all four 
sectors of the liver, as confirmed by imaging. Unless tumor 
downstaging is cleary demonstrated after preoperative 
chemotherapy, as may be the case when the anatomical border of 
an uninvaded liver sector is compressed without true malignant 
invasion, primary liver transplant seems to be the best option. 
iii. Unifocal, centrally located tumors involving main hilar structures 
or main hepatic veins, which would not become free of tumor even 
after an overall good response to chemotherapy and therefore not 
amenable to partial hepatectomy. 
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An absolute contraindication to liver transplantation is the 
persistence of extrahepatic deposits not amenable to surgical excision 
following chemotherapy.  
In patients who undergo primary liver transplantation for 
hepatoblastoma following neoadjuvant chemotherapy, 10-year survival 
rates of 85 % have been reported [77].  Tumor recurrence is more 
frequent in children with a previous attempt at hepatic resection. In 
patients who undergo "rescue" liver transplantation following partial 
hepatectomy, the 5-year overall survival is 30% to 50%. Positive margins 
after an initial attempt at resection is associated with a poor prognosis. 
Therefore heroic attempts at partial hepatectomy should be avoided, and 
liver transplantation should be considered when the potential for 
complete resection is in question [77]. 
For hepatocellular carcinoma, liver transplantation has the 
theoretical advantage of removing not only the tumor but also the entire 
diseased preneoplastic liver. The scarcity of cadaveric donors, especially 
in the pediatric age group, has led to the use of segmental grafts from 
living donors or split-liver cadaveric donors. Living, related donor 
transplantation for tumors has been associated with improved graft 
survival and outcome [40]. Disadvantages of transplantation include the 
associated expense and risks of lifelong immunosuppression, which may 
enhance tumor recurrence or secondary malignancies. 
Primary Orthotopic Liver Transplant (OLT) promises to be the 
future for children with advanced liver tumors not amenable to liver 
resections. 
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MATERIALS AND METHODS 
This study on liver tumors in children is based on 34 patients 
admitted to the Institute of Child Health and hospital for children [ICH & 
HC], Egmore during the period from January 2005 to December 2009. 
The study includes 24 boys and 10 girls between the age group 6 days to 
9 years. Data collected for each patient had been recorded in the enclosed 
chart. 
 The body weight at presentation was documented in all cases. All 
the 34 children underwent a detailed analysis of symptoms and a 
thorough clinical examination before management. 
 Antenatal history was documented in children presenting in the 
newborn period and findings of the antenatal scans were 
documented. 
 All children underwent the routine panel of blood investigations 
like complete blood counts, renal function tests and liver function 
tests. 
 Coagulation profile (prothrombin time, activated partial 
thromboplastin time, INR), was documented in all children before 
surgery or biopsy. 
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 A routine skiagram and CT scan of the chest was taken to 
document the pulmonary status of the patient. 
 The diagnosis of liver tumor and the possible pathological type was 
based on imaging studies. Ultrasound abdomen was the initial 
baseline study done to confirm the anatomic origin and extent of 
the tumor. The presence or absence of ascites, lymph nodes and the 
involvement of vascular structures like the portal vein, hepatic 
veins and IVC was also noted. Duplex and colour Doppler 
ultrasonography was used to document a prominent hepatic artery, 
portal vein and arteriovenous shunting in hemangioendothelioma. 
Ultrasound abdomen was also used to follow up patients during 
preoperative chemotherapy and in the post operative period to 
document the response and to identify any local recurrence. 
 Contrast enhanced CT scan was mandatory in all patients before 
neoadjuvant chemotherapy or liver resection, to better delineate the 
anatomy, the extent of the tumor and to plan the extent of resection 
preoperatively. 
 MR Imaging was done in 1 patient with hemangioendothelioma, 
presenting as a huge abdominal mass in the newborn period.  
 The most important investigation in the preoperative workup was 
tumor markers. Alpha feto protein(AFP) and beta HCG were done 
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in all patients. These were also used in the follow up period to 
document recurrence and disease progression. 
 The diagnosis was confirmed by tissue biopsy in all but 3 cases of 
malignant liver tumor (hepatoblastoma), where the AFP was 
hugely elevated, prior to liver resection or neoadjuvant 
chemotherapy. In cases where imaging and tumor markers was 
suggestive of a benign tumor like hepatic adenoma, a liver biopsy 
was avoided prior to treatment.     
 All children were registered with the Tumor Board at ICH and the 
treatment strategy was discussed extensively by a panel consisting 
of the paediatric surgeon, medical oncologist and pathologist. 
Parents were also involved in the process of decision making. 
 The PRETEXT system of staging was used for malignant tumors 
prior to neo adjuvant chemotherapy. 
 Children with unilobar resectable tumors were taken up for primary 
liver resection. Children with a large primary tumor and bilobar 
involvement were considered unresectable and were given 
neoadjuvant chemotherapy prior to surgical resection. Since ours is 
an institution with many consultants, hepatic resections were 
performed by different surgeons.  
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 Before surgical removal of the tumor, blood counts and parameters 
including the coagulation profile were confirmed to be within 
normal limits. 
 Children were kept nil by mouth for 6 hours prior to the surgery. 
The incision was planned and marked out. General anaesthesia 
(ETGA) with epidural analgesia was administered in all patients. 
Central venous access was secured prior and arterial pressure 
monitoring was done in all patients during the surgical procedure. 
Bladder was catheterized using foley catheter to monitor the 
output. At laparotomy the resectability and tumor extent was 
assessed prior to mobilization of the liver. Portal dissection and 
vascular control was achieved before parenchymal dissection. 
Parenchymal dissection was carried out with thermal cautery and 
the finger fracture technique. Perfect hemostasis was secured prior 
to wound closure. Intraoperative blood losses were replenished 
with fresh whole blood or packed cells.  
 All children were intensively monitored at the surgical ICU for 
stability of vital parameters. Pain relief was provided via the 
epidural catheter. The blood sugar, renal and liver function tests 
were monitored in the postoperative period. Children were shifted 
out of ICU to the general ward on the 5th or 6th post operative 
period, depending upon the general condition. 
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 Chemotherapy was given to all children with malignant liver 
tumors only. Chemotherapeutic schedule and drug dosing for 
malignant liver tumors was tabulated at the tumor board meet in 
consultation with the medical oncologist. All chemotherapeutic 
schedules were platinum based. The regimens followed were: 
HEPATOBLASTOMA VPF 
MALIGNANT MESENCHYMOMA PVC 
ENDODERMAL SINUS TUMOR  BEP 
EMBRYONAL SARCOMA PA 
V – vincristine, P – cisplatin, F – 5fluorouracil, B – bleomycin,  
E – etoposide, A – adriamycin, C – cyclophosphamide. 
 
VPF, PVC, PA were given in a once in 21 days cycle up to a 
maximum of 8 cycles depending upon the response. BEP regimen 
consisted of 6 weekly doses of bleomycin and 4 cycles of EP every 21 
days. Blood counts were closely monitored before and after 
chemotherapy. Parents were counseled on the possible side effects of 
chemotherapy and the need to be compliant for every cycle. The drug 
dosage was as follows: 
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CISPLATIN 100 mg/m2 in divided doses for 3 days 
VINCRISTINE 1.5mg/m2 per day 
5 – FLUOROURACIL 600mg/m2 per day 
ADRIAMYCIN 40mg/m2 in divided doses for 2 days 
BLEOMYCIN 15-20U/m2/week for 5 weeks 
ETOPOSIDE 100mg/m2/day for 3 days 
CYCLOPHOSPHAMIDE 1 gram/m2 in divided doses for 3 days 
 
Chemotherapeutic schedule for patients with recurrent disease was  
CISPLATIN 100 mg/m2 in divided doses for 3 days 
ADRIAMYCIN 40mg/m2 in divided doses for 2 days 
 
Benign liver tumors did not warrant any chemotherapy. 
 Follow up of patients who completed chemotherapy after surgery 
(n = 8) with the tumor board is as follows: 
1 Monthly visits for 1 year Blood counts, USG abdomen, 
AFP 
2 3 monthly visits (total of 6 visits) 1+CXR 
3 6 monthly visits for 1 year 1+2 
4 Yearly visits thereafter 1+2 
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Patients on chemotherapy after surgery (n = 1) have blood counts, 
abdominal sonography and tumor markers prior to every cycle of 
chemotherapy and CXR at 3 monthly intervals till they complete 
chemotherapy. Once chemotherapy is completed the follow up is as 
shown above. 
Patients with recurrent disease (n = 3) during follow up undergo 
CT scan of abdomen and chest in addition to other investigations and are 
started on the schedule for recurrent disease. 
Children who completed chemotherapy after liver resection were 
also closely monitored during follow up for weight gain, achievement of 
normal developmental milestones, scholastic performance and for 
maintenance of normal liver function with adequate regeneration of the 
remnant liver. 
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OBSERVATIONS 
This study conducted at ICH & HC is a prospective cum 
retrospective study done between January 2005 and December 2009 and 
it encompasses a total of 34 children admitted to the hospital with liver 
tumors both benign and malignant. The total number of boys was 24 
(71%) and the total number of girls was 10 (29%). The youngest age at 
presentation was 6 days and the oldest child was 9 years. The mean age 
was 3 years. 
Of the 34 children in the study, 33 children were symptomatic at 
presentation. The most common presenting symptom was mass in the 
abdomen (44%) noted by the parents. Abdominal distension was the next 
common complaint (41%). One third of the children has abdominal pain 
as their primary complaint and localized most commonly to the right 
hypochondrium. Jaundice was the presenting complaint in one patient at 
40 days of life and was incidentally found to have a 
hemangioendothelioma on abdominal sonography. Nonspecific 
complaints like fever, loss of appetite and weight were noted in 9 children 
(26%). 
Three children presented to us in the neonatal period and ante natal 
diagnosis with ultrasound was possible in 2 neonates with infantile 
hemangioendothelioma resulting in early diagnosis and treatment. 
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Hepatomegaly with a palpable firm mass was the most consistent 
finding in majority of the children (94%) presenting with liver tumor.  
Pallor was noted in 16 (47%) patients and correlated with a fall in 
hemoglobin levels. None of the 34 children demonstrated 
thrombocytopenia or congestive cardiac failure, especially those with 
infantile hemangioendothelioma where the kasabach merritt syndrome is 
a known association. 
Chest X Ray and CT chest taken on initial presentation was normal 
in all children with malignant liver tumors under the study. 
Liver function tests (serum bilirubin, SGOT, SGPT) were normal 
in all the patients except for the 1 child with infantile 
hemangioendothelioma, where the total bilirubin was elevated. 
Tumor markers: 
a. AFP – found to be elevated in 80% of patients with hepatoblastoma 
(16/20) and both patients with germ cell tumor. 20 % of children 
with hepatoblastoma (4/20) had normal AFP levels on presentation. 
Levels of AFP were normal in all other patients with other hepatic 
tumors. The AFP levels on follow up was found to be elevated in 3 
patients (2 hepatoblastoma and 1 germ cell tumor), correlating with 
disease recurrence.  
b. Beta HCG – was found to be normal in all patients with liver 
tumors. 
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ABDOMINAL IMAGING: 
 ULTRASONOGRAPHY 
USG was the basic initial imaging done to identify the organ of 
origin and extent of the tumor.  
9 In children with Hepatoblastoma the lesion was identified as a well 
defined, heterogenous or hypoechoeic lesion. Calcification within 
the tumor was noted in 2 cases of the mixed histological subtype. 
Thrombus in the portal vein branches was identified in 2 patients 
with hepatoblastoma. Endodermal sinus tumor was reported as 
hepatoblastoma. 
9 The USG of the child with embryonal sarcoma showed a cystic 
multi septated lesion from the right lobe of liver. 
9 Mesenchymal hamartoma classically appeared as a large, 
multilocular, cystic mass with internal septation without 
calcification in all the 5 children with this type of tumor. 
9 Hemangioendothelioma was seen as a heterogenous lesion with 
focal areas of increased echogenicity and prominent hepatic artery 
and portal vein on duplex and color Doppler. But the diagnosis had 
to be confirmed by an MRI in one of the 3 children with this tumor. 
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 CONTRAST ENHANCED CT SCAN OF ABDOMEN 
9 Hepatoblastoma presented as a homogenous or heterogenous lesion 
with peripheral rim enhancement classically seen in the mixed 
subtype. CT was able to better delineate the extent of involvement 
of lobes, compression or displacement of adjacent organs, status of 
lymph nodes, ascites and involvement of the portal vein and IVC. 
This information was very useful in planning the surgical 
procedure without any intra-operative surprises. 
9 Embryonal sarcoma was identified as a hypodense septate lesion 
with rim enhancement. But the USG and CT findings had to be 
correlated with tumor markers in a retrospective manner for 
accurate histological diagnosis. 
9 Mesenchymal hamartoma was seen as a large, multilocular, cystic 
mass with internal septation without calcification. 
9 Definite diagnosis of Hepatic adenoma was not possible as the 
lesion  appeared as a nonspecific solitary, hypodense, non-
enhancing lesion.    
 MAGNETIC RESONANCE IMAGING: 
9 MRI was specifically useful in one child with infantile 
hemangioendothelioma and was seen as a large hypointense lesion 
on T1 and mixed intense lesion on T2 weighted images. 
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STAGING 
The staging was done using the PRETEXT staging system and 
stage 2 was the most commonest and the remaining cases were stage 4 
disease. 
HISTOPATHOLOGY: 
The percentage of malignant liver tumors in the study was 74% 
(25/34). The percentage of benign tumors was 26% (9/34). The most 
common malignant liver tumor was hepatoblastoma [80% (20/25)]. Of 
the 20 cases, 7 were of the fetal subtype, 3-embryonal, 2-macrotrabecular, 
1-anaplastic and 7 were of the mixed histological subtype. The most 
common benign liver tumor was mesenchymal hamartoma [56% (5/9)]. 
There were no cases of hepatocellular carcinoma, hemangioma, 
rhabdomyosarcoma in the study. The distribution of the different tumors 
is shown in the bar diagram.   
MALIGNANT Hepatoblastoma 20 
 Malignant mesenchymoma 1 
 Endodermal sinus tumor 2 
 Undifferentiated Embryonal 
sarcoma 1 
 Secondaries liver 1 
 
BENIGN Mesenchymal hamartoma 5 
 Infantile hemangioendothelioma 3 
 Hepatic adenoma 1 
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TREATMENT  
SURGICAL MANAGEMENT 
 As noted above, of the 34 children studied, 25 had a malignant 
tumor and 9 had a benign tumor. 
 Of the 25 children with a malignant tumor, 17 underwent liver 
resection. 
 Of the 9 children with a benign tumor, 7 underwent surgical 
removal of tumor. 
 Right hepatectomy (removal of segments 5,6,7,8) was performed in 
14 children with right lobe tumor [ 9-hepatoblastoma, 1-infantile 
hemangioendothelioma, 2-mesenchymal hamartoma, 1-malignant 
mesenchymoma, 1-embryonal sarcoma]. 
 Left hepatectomy (removal of segments 2,3,4) was performed in 3 
children with left lobe tumor [all 3 for hepatoblastoma]. 
 Wedge resection (removal of tumor with a margin of normal liver) 
was done in 3 patients [1-hepatic adenoma, 1-hepatoblastoma, 1-
endodermal sinus tumor]. 
 Total excision of tumor alone was done in 4 patients [3-
mesenchymal hamartoma, 1-endodermal sinus tumor].   
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   MALIGNANT 
(n=17) 
BENIGN 
(n=7) 
SURGERY 
(n=24) 
RIGHT 
HEPATECTOMY 
11 3 
 LEFT HEPATECTOMY 3 0 
 WEDGE RESECTION 2 1 
 TOTAL EXCISION 1 3 
 
TUMOR BIOPSY ONLY: 7 of the 25 children with malignant 
tumors had advanced disease at presentation and underwent only a biopsy 
to confirm the diagnosis. 
CONSERVATIVE MANAGEMENT: 3 of the 34 children were 
managed conservatively [2-hemangioendothelioma which resolved 
spontaneously, 1-secondaries from neuroblastoma]. 
CHEMOTHERAPY 
 NEOADJUVANT CHEMOTHERAPY  
8 of the 17 children who underwent surgery for a malignant liver 
tumor had neoadjuvant chemotherapy. 1 child died in the immediate 
postoperative period due to hypovolemic shock.  
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 ADJUVANT CHEMOTHERAPY 
9 of the 17 children underwent primary liver resection before 
adjuvant chemotherapy. 3 died in the immediate post operative period 
due to hypovolemic shock. 
CHEMOTHERAPY 
(n=17) 
NEOADJUVANT 8 
 ADJUVANT 9 
 
OUTCOME 
9 The outcomes of this study are based on follow up data 
documented with the ICH tumor board and data collected by 
contacting parents through telephone or by postcards dispatched to 
their residence. 
9 The follow up period ranges from 2 months to 5 years with a mean 
follow up period of 3 years. 
9 16 of the 24 children who were operated (67%) are alive and are on 
regular follow up.  
9 56% (9/16) of those on regular follow up have survived a 
malignant liver tumor [7-hepatoblastoma, 1-malignant 
mesenchymoma, 1-endodermal sinus tumor]. 
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9 The growth pattern and developmental milestones were similar to 
healthy children. The liver function tests were normal on follow up 
in all children who survived the disease and their ultrasonogram 
showed adequate compensatory hypertrophy of the remaining liver 
with no recurrence of the disease. Children who were of the school 
going age were found to have a normal scholastic performance and 
there were no drop outs.  
9 Children operated for benign tumors are all alive and there has 
been no mortality or disease recurrence in this group. 
9 Tumor recurrence after surgery occurred in 3 of the patients. These 
include wedge resection for hepatoblastoma and endodermal sinus 
tumor, right hepatectomy for undifferentiated embryonal sarcoma. 
9 Neoadjuvant chemotherapy is advantageous in terms of reduction 
in tumor size and therefore easier tumor handling and less per 
operative blood loss. Only one patient died in the immediate post 
operative period due to hypovolemic shock.  
9 On the contrary 3 deaths were noted with the adjuvant 
chemotherapy group were due to difficulty in handling a large 
tumor at primary liver resection leading to massive intra-operative 
blood loss or IVC tear. 
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DISCUSSION 
Liver tumors, one third of which are benign, constitute 1.1% of 
childhood tumors [40]. The management of liver tumors in children has 
undergone a paradigm shift over the last 30 years. In the past decades, 
there were reservations to the use of chemotherapy in patients especially 
before surgery owing to the belief that chemotherapy was likely to 
adversely affect intra and post operative outcomes [66]. Another long 
held myth was that heroic liver surgery was the key to successful 
management. Improvements in radiological imaging, advances in the 
understanding of chemotherapy, improved surgical technique of liver 
resection, and the advances in paediatric liver transplantation have 
contributed to the favorable, outcome, of children afflicted with liver 
tumors. 
In this study at ICH & HC, we had 34 patients in all, presenting 
with liver tumors and it includes both benign and malignant lesions. Since 
ours is an institution with many different consultants, liver resections 
were done by more than one surgeon. The data collected has been 
analyzed and compared to the world literature.  
AGE AND SEX DISTRIBUTION  
The age distribution of the various pediatric liver tumors as per 
Von Schweinitz D [1] is shown in table 1: 
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In the youngest children, infants and toddlers, most malignant 
tumors are hepatoblastomas [1]. In older children the most common 
primary malignant liver tumor is hepatocellular carcinoma [2]. Tumors in 
intermediate age children, with features of both hepatoblastoma and HCC 
have been described as transitional cell tumors [78].  In the Indian 
context, in a study done by Minu Bajpai et al the age for hepatoblastoma 
varied from 16-38 months and the male female ratio was 1.5:1 [79]. In 
our study, there were a total of 24 boys and 10 girls.  
The age and sex distribution of various malignant liver tumors is 
shown in the bar diagrams.  
ANALYSIS OF SYMPTOMS IN COMMON LIVER TUMORS 
ICH & HC is a government run institution and caters to the 
children belonging to the lower socio economic strata. Majority of 
parents of children with liver tumors are illiterate and ignorant of even the 
common paediatric problems. This is one of the reasons why a good 
number of our patients in the study presented to us in the advanced stage 
of the disease.  
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Most of our children presented with a mass in the abdomen or with 
abdominal distension, which was either noticed by the parents or by the 
referring physician. The following table compares the presenting 
complaints of the children in our study with the study done by Exelby PR 
et al [80].  
MALIGNANT – HEPATOBLASTOMA 
 Exelby PR et al 
[80] % 
ICH & HC 
% 
MASS ABDOMEN 75 45 
DISTENSION 23 45 
PAIN 22 20 
FEVER Rare 25 
WEIGHT LOSS 26 5 
ANOREXIA 25 5 
VOMITING 12 5 
JAUNDICE 5 5 
 
The most common benign tumor in our series was mesenchymal 
hamartoma. All children presented with abdominal distension. The table 
below compares the presenting complaints in our series with those of the 
study by Jonathan S K et al [81]. 
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BENIGN – MESENCHYMAL HAMARTOMA 
 Jonathan S K et al [81] % ICH & HC% 
DISTENSION 100 100 
VOMITING 50 20 
PAIN 12.5 40 
RESPIRATORY 
DISTRESS 
12.5 NIL 
 
ANTENATAL DIAGNOSIS 
Primary liver tumors are very rare during the neonatal period, but 
increasing numbers of them are now diagnosed prenatally by routine 
ultrasound scan, therefore perinatal emergency situations can be avoided 
[83]. In our series, 2 children had antenatal scans suggestive of a 
hemangioendothelioma of the liver. One child was operated in the 
newborn period and the other had a spontaneous resolution of 
hemangioendothelioma on follow up. 
TUMOR MARKERS 
The most important tumor marker is the alpha-fetoprotein (AFP), 
because it is highly elevated in 80% to 90% of all Hepatoblastoma [1] 
and tumors which fail to express AFP at diagnosis are felt to be 
biologically more aggressive [29][30]. It has to be taken into account that 
it can also be highly elevated in malignant teratoma and yolk sac tumors 
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of the liver. Also important is the consideration of its wide range during 
the first years of life, with normal levels exceeding 500,000 ng/mL in 
neonates and 300 ng/mL in 3-year-old children [1]. Notably, most 
neonatal Hepatoblastomas do not produce enough AFP to produce serum 
levels markedly above the normal range. In our study at ICH & HC there 
were 4 children with hepatoblastoma (20%) with normal AFP (3-mixed 
subtype and 1-macrotrabecular subtype) and only one of the 4 has 
survived the disease.   
HISTOPATHOLOGY: 
The prognosis for liver tumors depends to a large extent on the 
histology of the tumor. Benign tumors have a uniformly good prognosis, 
and in our series of 34 children with 9 benign tumors there was no noted 
mortality. Histopathology of malignant tumors determines the response to 
treatment, thereby affecting the outcome, the fetal subtype of 
hepatoblastoma is a favourable histologic pattern [82] and was seen in 6 
of our patients. The anaplastic subtype, was seen in 1 patient, who had 
advanced disease at presentation and did not respond to treatment. Mixed 
histology with mesenchymal component behaves in between the two and 
was found in 7 of our patients with hepatoblastoma. 
In the study by Saniye Ekinci and Ibrahim Karnak et al [82] in 
2006 from Turkey where 25 hepatic lobectomies were performed over 25 
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years, the histopathological distribution of tumors was as shown in the 
chart: 
HISTOPATHOLOGICAL DISTRIBUTION 
Hepatoblastoma 11 
Mesenchymal Hamartoma 5 
Hepatocellular carcinoma 4 
Hemangioendothelioma 1 
Malignant mesenchymal tumor 1 
Hemangioma 1 
Metastases  1 
Hepatic adenoma 1 
 
In our study at ICH & HC over a period of 5 years, the distribution 
of tumors was akin to the one reported above. The most common 
malignant liver tumor was hepatoblastoma. We had no reported case of 
hepatocellular carcinoma in our series. 
MALIGNANT Hepatoblastoma 20 
 Malignant mesenchymoma 1 
 Endodermal sinus tumor 2 
 Undifferentiated Embryonal 
sarcoma 1 
 Secondaries liver 1 
 
BENIGN Mesenchymal hamartoma 5 
 Infantile hemangioendothelioma 3 
 Hepatic adenoma 1 
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TREATMENT 
There are a wide range treatment options available for the 
management of liver tumors and these include liver resections, 
chemotherapy, radiotherapy, ablative therapies and liver transplantation. 
Hepatic resection is a fundamental treatment and is the gold standard for 
malignant and benign hepatic tumors of children and complete surgical 
removal of the tumor is the primary goal of any liver resection. Surgery 
of the liver has a special point in paediatric surgical practice. Liver is one 
of the most difficult organs a surgeon can operate upon because of its 
friable tissue with an intricate network of ducts, veins, and arteries. Major 
vascular structures, particularly the hepatic veins and inferior vena cava 
are prone to bleeding during resection. On the other hand, liver’s 
regenerative capability and large functional reserve allow major 
resections of up to 80% of its tissue. Experience of surgeon, familiarity to 
complex hepatic anatomy and strict follow of anatomic planes directly 
affect results. Resection becomes more comfortable in cases with 
malignant liver tumors, which are initially treated by preoperative 
chemotherapy.  
Benign liver tumors in childhood have long been associated with 
poor prognosis mostly due to surgical complications. Surgical treatment 
should be considered selectively in patients with benign liver tumors, 
especially with hemangiomas. Along with the technical advances in 
surgery and diagnostic tests, surgical treatment became feasible in benign 
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liver tumors of childhood in selected patients. In this series, 26% (9/34) 
of patients had benign tumors and total resection was possible in 7 
without any morbidity or mortality. 
The details of the hepatic resections from the study by Saniye 
Ekinci and Ibrahim Karnak et al [82] in 2006 from Turkey is shown 
below: 
DETAILS OF HEPATIC RESECTIONS n = 25 
Right hepatic lobectomy 12 
Left hepatic lobectomy 5 
Extended left hepatic lobectomy 4 
Extended right hepatic lobectomy 3 
Enucleation of tumor 1 
 
The details of hepatic resections at ICH & HC is as follows: 
  MALIGNANT 
(n=17) 
BENIGN
(n=7) 
SURGERY 
(n=24) 
RIGHT 
HEPATECTOMY 
11 3 
 LEFT HEPATECTOMY 3 0 
 WEDGE RESECTION 2 1 
 TOTAL EXCISION 1 3 
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The following table shows a comparison of the complications 
noted in our study with the Turkish group: 
 Saniye Ekinci 
and Ibrahim 
Karnak et al [82] 
ICH & HC
Intra operative cardiac arrest due to 
hypovolemia 
1 1 
IVC injury 1 3 
Bile leak 1 1 
Fever 3 1 
Jaundice 3 NIL 
Ileus 2 NIL 
Metabolic NIL NIL 
DIC 2 NIL 
 
The overall mortality in the Turkish study was 12% with 2 early 
postoperative and 1 late postoperative deaths [82] as compared to our 
study with a mortality rate of 16% in the immediate postoperative period 
(4 deaths). 
Although adjuvant chemotherapy and radiotherapy have improved 
the prognosis of malignant tumors, complete surgical resection is still the 
main stay of the treatment [84][85]. Even though hepatoblastomas can be 
resected by primary operation, preoperative chemotherapy should preceed 
the operation in case of large tumors even when there is possibility of 
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resection [58]. This strategy helps preserve more mass of healthy hepatic 
tissue and decrease intraoperative and postoperative complications. 
In our series out of 17 patients who underwent surgery for a 
malignant hepatic tumor, 8 were given preoperative chemotherapy and 
tumors became resectable in all cases. There was only one immediate 
postoperative death due to intra-operative blood loss. We attribute the 
decreased intra-operative blood loss to two factors: (1). Marked reduction 
in tumor size due to preoperative chemotherapy and (2) prior isolation of 
vessels supplying the area to be removed (initial isolation of the vessels at 
the hilum and outside the liver substance, followed by ligation and 
division of these structures and subsequent parenchymal transaction). But 
of the 9 children who were operated without preoperative chemotherapy, 
3 died in the immediate postoperative period due to blood loss during 
surgery. This finding is akin to the observation made in the study on the 
effect of preoperative chemotherapy for hepatoblastoma by Minu Bajpai 
et al [79]. Before the era of preoperative chemotherapy, perioperative 
mortality was 10%. Excessive blood loss was the most common 
complication and was followed by cardiac arrest [80].   
The high rate of resectability after chemotherapy in unresectable 
cases and increased survival emphasize the advantage of preoperative 
chemotherapy. 
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FOLLOW UP 
The shortest and longest follow up in our study at ICH & HC are 2 
months and 5 years respectively. The average follow up was 36 months. 
The primary predictor for poor prognosis in hepatoblastoma and 
hepatocellular carcinoma is metastatic disease. Multifocality, size, and 
lack of response to chemotherapy are also predictive of poor prognosis in 
hepatocellular carcinoma. Although metastatic disease portends a worse 
prognosis, some metastatic lesions have a complete response to 
chemotherapy. Pulmonary resection should be considered in selected 
patients with lung lesions that persist after chemotherapy. Following 
hepatic resection, most patients receive postoperative chemotherapy. 
Patients should be followed closely to ensure that serum AFP levels 
return to normal and that the neoplasm does not recur. In those patients 
who present with normal AFP levels, serial ultrasonography or CT can be 
performed to screen for recurrence. 
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CONCLUSION 
Surgery of liver has a special point in paediatric surgical practice 
because Hepatic tumors are major disorders affecting children with high 
morbidity and mortality rates. This study covers 34 patients over a 5 year 
period and compares well with other established centers in India and 
around the world. The results are not as abysmal as previously thought of. 
Experience of the surgeon, familiarity to complex anatomy, strict 
adherence to anatomical planes, advances in anaesthesia, surgical 
technique, use of newer surgical tools (like CUSA, Intraoperative 
ultrasound, staplers etc) and chemotherapy have led to a significant 
improvement in the prognosis of children with hepatoblastoma. 
Outcomes for hepatocellular carcinoma remain poor. Anatomical 
resection becomes more comfortable in malignant tumors which are 
initially treated by preoperative chemotherapy. Liver transplantation is 
useful in patients with unresectable tumors. 
Long term goal of the centers undertaking major hepatic resections 
for liver malignancies in children must be pre tuned to liver 
transplantation, which will become the gold standard in the management 
of liver tumors in children in the future. Continued cooperation of multi-
institutional pediatric cancer study groups will be required to achieve 
additional advances in the treatment of malignant liver neoplasms. 
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PROFORMA 
INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR 
CHILDREN DEPARTMENT OF PAEDIATRIC SURGERY 
EGMORE, CHENNAI. 
 
LIVER TUMORS IN CHILDREN 
Name              Age              Sex                      IP No.                        Wt 
 
 
Presenting complaints 
ASYMPTOMATIC 
MASS 
ABDOMEN 
ABDOMINAL 
PAIN 
ABDOMINAL 
DISTENSION 
JAUNDICE 
 
OTHERS 
      
 
Past history 
Antenatal history 
Clinical findings 
 
MASS ABDOMEN ICTERUS PALLOR 
ASCITES 
 
OTHER FEATURES 
     
 
Associated anomalies      
HAEMANGIOMA 
CONGESTIVE CARDIAC 
FAILURE 
THROMBOCYTOPENIA OTHERS 
    
 
Investigations done 
 
Plain x ray 
(CHEST/ABDOMEN) 
 
Usg abdomen  
BLOOD  
TUMOUR MARKERS  
CECT  
LAPAROSCOPY/BIOPSY  
Others  
 
HISTOPATHOLOGY 
 
BENIGN MALIGNANT 
  
 
Treatment given   
 
SURGERY CHEMOTHERAPY OTHERS 
 NEOADJUVANT ADJUVANT  
   
 
Outcome  
 
Recovery   Follow up   Complications 
 
 
  
 
